Ontology highlight
ABSTRACT: Background
In observational studies, patients with HIV have higher levels of soluble ST2 (sST2), galectin-3, and growth differentiation factor-15 (GDF-15) than non-HIV controls. As statins exert pleiotropic immunomodulatory effects that may affect markers of myocardial fibrosis, the objective of the current study is to determine whether biomarkers of myocardial fibrosis reflecting subclinical pathology may be modified by statin therapy in patients with HIV.Setting and methods
Forty HIV+ men and women participated in a single center 12-month randomized, double-blind placebo-controlled trial of atorvastatin 40 mg every day vs. placebo. At baseline and 12-months, sST2, GDF-15, galectin-3 were measured.Results
The changes in sST2 were -0.310 (-4.195, 2.075) vs. 1.163 (0
SUBMITTER: deFilippi C
PROVIDER: S-EPMC5889348 | biostudies-literature | 2018 May
REPOSITORIES: biostudies-literature